From the CEO
Alzheimer’s disease affects about 6 million Americans and 50 million patients worldwide.
Current medications provide limited relief.
Many of our competitors are focusing on removing either Abeta or tau deposits from the brain where they form plaques and tangles. None of these efforts have generated any effective drug for the last 18 years since the first anti-Abeta trial started.
The idea that Abeta and plaque do not cause Alzheimer’s is gaining momentum in the research community; we were determined to look for a different solution prior to the formation of the plaques.
Our novel approach focuses on Leptin, a naturally occurring human hormone associated with various metabolic effects, which has a large number of receptors in memory centers of the brain.
Hippocampus (in red) responsible for memory formation, cognition and executive function is severely affected by the disease. This region is rich in Leptin receptors.
This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels.
We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients.
This Leptin product may act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.
Alzheimer's is the fifth-leading cause of death among those aged 65 and older and is also a leading cause of disability and poor health. An estimated 5.8 million Americans aged 65 and older were living with Alzheimer's dementia in 2020. 80% of this population was aged 75 or older. This number is expected to increase to 13.5 million by 2050. Among people of age 70, 61% of those with Alzheimer's dementia are expected to die before the age of 80 compared with 30% of people without Alzheimer's. The rising prevalence of Alzheimer's disease has increased the demand for the treatment, which in turn is expected to boost the market growth. (2020 Alzheimer's disease facts and figures)
success to date
- InvestAcure Coin Award 2019
InvestAcure honored Nik Tezapsidis with the Cure Coin Award for his work in the development of Memtin, a novel recombinant human Leptin product, used as a hormone replacement therapy, showing potential in both slowing down and preventing Alzheimer’s.
- 2010 Incubator Company to Watch
Neurotez was chosen as a 2010 Incubator Company to Watch at the NJTC Gala Awards
Previous Funding Total = $4.8M:
- National Institutes of Health
- IRS Qualifying Therapeutic Discovery Project Grant
- New Jersey Commission of Science and Technology
- Previous crowdfunding raise of $300k
An impressive group of exceptional individuals with deep experience and success in their respective fields in Academia (100s of publications in Alzheimer’s) and Pharmaceutical Industry have been working together for a number of years to achieve our mission.
Use of Proceeds
If the offering's maximum amount of $500,000 is raised:
|Use||Value||% of Proceeds|
|Compensation for managers||$120,000||24.0%|
|Research and Development||$230,500||46.1%|
|Taxes and Fees||$5,000||1.0%|
This is an offering of Common Stock, under registration exemption 4(a)(6), in Neurotez Inc.. This offering must raise at least $10,000 by January 27, 2023 at 9:00pm ET. If this offering doesn’t reach its target, then your money will be refunded. Neurotez Inc. may issue additional securities to raise up to $500,000, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
These financial statements have been reviewed by an independent Certified Public Accountant.
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
- Jan 28, 2023Primary offering finalized, sellingsharesSold $4 for a total of $15,952shares at
- Jan 26, 2023
- Dec 10, 2022Join us tomorrow : BIOTECH PLANET International...
Join us tomorrow : BIOTECH PLANET International Conference December 11th, 2022Learn about Neurotez
- Nov 23, 2022From the President and CEO, Nikolaos...
From the President and CEO, Nikolaos Tezapsidis: “I wish all our current and future investors and supporters wonderful and joyful holidays. Thanking you for believing in us and helping us in our efforts to deliver something much needed to all families: a meaningful treatment for Alzheimer’s disease patients and potential preventative for those at risk. God bless.”
- Nov 3, 2022
- Oct 27, 2022
- Sep 12, 2022
- Sep 9, 2022We are very delighted to announce the addition...
We are very delighted to announce the addition of Royston G King to our advisory Board….(https://lnkd.in/eYD5DYi7) Royston G King is a self-made & world-renowned multi-millionaire award-winning 8-figure serial entrepreneur, multiple best-selling author, celebrity socialite media personality, most coveted TEDx & keynote speaker, & world’s leading preeminent philanthropist. Partner & advisor to celebrities, billionaires, royal family brands, billion-dollar brands, public-listed companies, New York Times best-selling authors, social media verified (actors, pro athletes, musicians, entrepreneurs, personal brand influencers, etc.), Fortune500, Forbes 1000, Inc5000, & the world’s biggest brands Investor & board of advisor to 100+ companies across hundreds of all types of industries & 6 continents. All with enterprise value surpassing USD $1+ billion.
- Sep 1, 2022Primary offering of $4shares at
- Sep 1, 2022
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email firstname.lastname@example.org instead of commenting.